← Gordon B. Mills

Papers by Gordon B. Mills

Page 3 · newest first

101. Supplementary Methods and Figure Legend from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP12023
102. BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumorsJournal for ImmunoTherapy of Cancer · 2023
103. Data from Pharmacodynamic Markers of Perifosine Efficacy2023
104. Data from Pharmacodynamic Markers of Perifosine Efficacy2023
105. Data from Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer2023
106. Data from Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer2023
107. Data from Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer2023
108. Data from Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set2023
109. Supplementary Data from Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer2023
110. Supplementary Data from Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer2023
111. Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer2023
112. Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer2023
113. Data from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma2023
114. Data from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma2023
115. Data from Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling2023
116. Data from An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer2023
117. Data from 3-Phosphoinositide–Dependent Kinase 1 Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma2023
118. Supplemental Figure 3 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics2023
119. Supplementary Methods from Identification of Optimal Drug Combinations Targeting Cellular Networks: Integrating Phospho-Proteomics and Computational Network Analysis2023
120. Supplementary Methods from Identification of Optimal Drug Combinations Targeting Cellular Networks: Integrating Phospho-Proteomics and Computational Network Analysis2023
121. Data from Steroid Receptor Coactivator-3 Expression in Lung Cancer and Its Role in the Regulation of Cancer Cell Survival and Proliferation2023
122. Supervised learning of high-confidence phenotypic subpopulations from single-cell data2023
123. PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived modelsBMC Medicine · 2023
124. Multi-omics characterization of silent and productive HPV integration in cervical cancerCell Genomics · 2023
125. L1CAM is required for early dissemination of fallopian tube carcinoma precursors to the ovaryCommunications Biology · 2022
126. Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysisCell Reports Medicine · 2022
127. [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot StudyClinical Cancer Research · 2022
128. Single cell RNA sequencing reveals C5aR1 inhibition to selectively target pro-tumorigenic M2 macrophages reversing PARP inhibitor resistance2022
129. Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targetsNature Communications · 2022
130. Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in CancerCancer Research · 2022
131. A multi-omic analysis of MCF10A cells provides a resource for integrative assessment of ligand-mediated molecular and phenotypic responsesCommunications Biology · 2022
132. Beyond BRCA: Discovery of novel causes and consequences of homologous recombination deficiencies2022
133. RPPA SPACE: an R package for normalization and quantitation of Reverse-Phase Protein Array dataBioinformatics · 2022
134. IMP1/IGF2BP1 in human colorectal cancer extracellular vesiclesAJP Gastrointestinal and Liver Physiology · 2022
135. BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancerCell Reports · 2022
136. A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cellsNeuro-Oncology · 2022
137. In vivofunctional characterization of EGFR variants identifies novel drivers of glioblastomaNeuro-Oncology · 2022
138. Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor ResistanceClinical Cancer Research · 2022
139. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatmentNature Communications · 2022
140. Biomolecular Condensation: A New Phase in Cancer ResearchCancer Discovery · 2022
141. HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumorsNature Communications · 2022
142. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugsNature Biotechnology · 2022
143. Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian CancerAdvanced Science · 2022
144. Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancersnpj Breast Cancer · 2022
145. Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical ResectionClinical Cancer Research · 2022
146. Spatial Heterogeneity of Infiltrating T cells in High-Grade Serous Ovarian Cancer revealed by Multi-omics analysis2022
147. A multi-encoder variational autoencoder controls multiple transformational features in single-cell image analysisCommunications Biology · 2022
148. Development of novel immunotherapy based on nanoparticle co-delivering PLK1 and PD-L1 inhibitors for lung cancer treatment2022
149. A functional genomic approach to actionable gene fusions for precision oncologyScience Advances · 2022
150. An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancerCell Reports Medicine · 2022